May 23, 2016 at 12:18 | Source: CNBC-TV18
Britannia has posted a double-digit volume growth despite a slackening demand in FY16. Amnish Aggarwal, Senior VP at Prabhudas Lilladher, maintained that the company will give a better performance in the years to come.
May 21, 2016 at 11:52 | Source: CNBC-TV18
Amisha Vora of Prabhudas Lilladher is of the view that JK Lakshmi Cement is one of the top picks.
May 20, 2016 at 18:57 | Source: CNBC-TV18
Dilip Bhat says that a combination of recent reforms like the Mauritius Treaty, P-Note amendment and a possible US Fed rate hike in June have been overwhelming for the market in the short term.
May 20, 2016 at 12:37 | Source: CNBC-TV18
R Sreesankar, Head Institutional Equities, Prabhudas Lilladher in an interview to CNBC-TV18 shared his rationale for picking Infosys, HDFC Bank, Aurobindo Pharma, Jubilant Life and Glenmark as his top picks.
May 20, 2016 at 10:41 | Source: CNBC-TV18
Drugmaker's management highly unlikely to achieve guidance, says Surajit Pal, analyst at Prabhudas Lilladher.
May 17, 2016 at 11:00 | Source: CNBC-TV18
Ajay Bodke of Prabhudas Lilladher is of the view that one can stay away from Bharat Forge and Motherson Sumi and feels that YES Bank may test Rs 1200 in the next 12-18 months.
May 17, 2016 at 09:42 | Source: CNBC-TV18
Ajay Bodke of Prabhudas Lilladher prefers Dabur India on dips and has Maruti Suzuki and Tata Motors as top picks.
May 17, 2016 at 09:33 | Source: CNBC-TV18
Ajay Bodke of Prabhudas Lilladher is of the view that Petronet LNG is the top buy idea with a target of Rs 300.
May 17, 2016 at 09:17 | Source: CNBC-TV18
Watch the interview of Rajat Bose of rajatkbose.com, Prakash Gaba of prakashgaba.com, Ashwani Gujral of ashwanigujral.com, Sandeep Wagle of powermywealth.com, Ajay Bodke of Prabhudas Lilladher, and Chandan Taparia of Anand Rathi Securities with Latha Venkatesh and Sonia Shenoy on CNBC-TV18.
May 12, 2016 at 11:36 | Source: CNBC-TV18
Two leading pharma companies, Dr Reddy's and Glenmark, are slated to post fourth-quarter earnings today and chances are both firms may disappoint, says Surajit Pal, Pharma Analyst at Prabhudas Lilladher.